BMO Capital Reiterates Outperform on Bristol-Myers Squibb (BMY)

January 25, 2019 8:45 AM
BMO Capital analyst, Alex Arfaei, reiterated an Outperform rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles